Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)

Study:

A Study Comparing Angiomax (Bivalirudin) to Heparin With Protamine Reversal in Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass (CPB)

Rationale:

n/a

Purpose:

The purpose of this study is to demonstrate that in patients undergoing coronary artery bypass grafting (CABG) or CABG-Valve, or Isolated Cardiac Valve surgery on CPB (cardiac surgery), Angiomax is a safe and effective alternative anticoagulant to heparin with protamine reversal.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Cardiovascular Disease
Coronary Artery Bypass Surgery
Drug: Heparin
Drug: Bivalirudin
Phase 3

Verified by The Medicines Company January, 2012

Sponsored by: The Medicines Company
Information provided by: The Medicines Company
ClinicalTrials.gov identifier: NCT00079586

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

The Cleveland Clinic
Cleveland, Ohio 44195
United States

Malcolm Lloyd, MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site